Serious injuries and symptoms discussed in Wegovy and GLP-1 litigation may include: Gastroparesis or delayed gastric emptying Stomach paralysis symptoms, including nausea, vomiting, bloating, abdominal pain, early fullness, and difficulty keeping food down Ileus or intestinal blockage Bowel obstruction or pseudo-obstruction Persistent vomiting and dehydration Malnutrition or inability to tolerate normal food intake Severe abdominal pain requiring emergency care or hospitalization Pancreatitis, which has been reported as a risk signal in GLP-1 research NAION-related vision loss, which should be evaluated separately from gastrointestinal injury claims These allegations do not mean every patient who used Wegovy has a claim
eIF2 phosphorylation is required to prevent hepatocyte death and liver fibrosis in mice challenged with a high fructose diet
So Melanotan is a pretty versatile peptide
While Bifidobacterium infantis and Clostridium butyricum have long safety histories in pregnant populations, Akkermansia muciniphila is a relatively novel probiotic ingredient with limited data in this context
10.1016/j.gene.2013.10.017 Gene
doi: 10.1038/nn.3413 190 SutcigilL.OktenliC.MusabakU.BozkurtA.CanseverA.UzunO.et al